ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Second-trimester multimetabolite panel for early preeclampsia rule-out.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveWe aimed to establish a high-sensitivity, multimetabolite rule-out model for the development of preeclampsia (PE), prioritizing minimizing false negatives to exclude low-risk individuals from intensive surveillance confidently.
methodsIn this prospective, nested case-control study, maternal serum samples were collected between 20
resultsCompared to the control group, univariate analysis revealed lower methionine and glutamine concentrations and elevated threonine levels in the case group. Classification models based on the remaining 33 metabolites, using leave-one-out cross-validation, achieved 100% sensitivity but had limited specificity (21%). A reduced four-metabolite model maintained 100% sensitivity with 50% specificity, while our refined, best-performing six-metabolite model achieved 100% sensitivity and 61% specificity with a negative predictive value of 100%.
conclusionOur models demonstrated considerable potential as diagnostic tools for ruling out PE, thereby reinforcing their future applicability in screening and monitoring strategies during gestation to improve clinical decision-making and alleviate the burden on healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.